MYCN and neuroblastoma: Our work still presents limitations regarding the used models, since although working with different molecular backgrounds (MYCN-amplified and TP53-deficient SK-N-BE(2) cells; MYCN-non-amplified and TP53-functional SH-SY5Y) these models neither comprise the totality of neuroblastoma molecular subtypes, nor represent the natural evolution and progression of the disease, as both cell lines were derived from bone-marrow metastases.